Conventionally prepared immune serum globulin frequently produces severe side effects when administered intravenously. A modified preparation in which 4 to 5 interchain disulfide bonds have been reduced and alkylated has been made for intravenous use. However, reduction and alkylation may affect Fc-mediated functions of immunoglobulin G, particularly its ability to fix complement by the classical pathway. To determine whether reduction and alkylation alters the protective activity of immune serum globulin in vivo we compared it with two less harshly prepared globulins (pH 4 treated or ultrafiltered) in an infant rat model of Haemophilus influenzae b infection. Antibody binding to the capsular and noncapsular components of H. influenzae b and in vitro bactericidal activity were similar in the globulin preparations. Infant rats were treated with various doses of globulins adjusted to provide identical concentrations of anticapsular antibodies as measured by the Farr radioactive antigen binding assay. At high doses of anticapsular antibody (>1,500 ng per pup), all preparations protected well. At marginal doses (750 ng per pup), however, rats given reduced and alkylated globulin had a significantly greater incidence of bacteremia (P < 0.05), meningitis (P < 0.01), and death (P < 0.05) and a higher magnitude of bacteremia (P < 0.02) than rats who received pH4-treated or ultrafiltered globulins. These differences were not due to differences in anticapsular antibody concentrations achieved in the serum. The 50% protective serum concentrations of anticapsular antibody in this model were 200 to 300 ng/ml for reduced and alkylated globulin and 100 to 200 ng/ml for acid-treated globulin. Absorption of the globulins with purified H. influenzae b capsule reduced in vitro bactericidal activity and rat protective activity. However, the magnitude of bacteremia was lower in rats receiving absorbed pH 4-treated globulin than in those receiving absorbed reduced and alkylated globulin (P < 0.05). We conclude that reduced and alkylated immunoglobulin G provides significantly less protective activity against H. influenzae b infection in this model than globulins not so modified, and we suggest that the altered Fc function of the immunoglobulin G, such as the decreased ability to fix complement by the classical pathway or decreased Fc-mediated opsonization, may be responsible for this impairment.
Human immune serum globulin (ISG) has been found to be useful in reducing infections in patients with humoral immune deficiencies (4, 15, 31) . The dose of ISG that can be administered has been limited by the necessity of intramuscular administration due to serious systemic side effects that occurred with intravenous use (4, 5) . Although the mechanism of these effects is not fully understood, spontaneous activation of complement by immunoglobulin G aggregates formed during the plasma fractionation process may be responsible (5, 23) . An (27, 28) , yielding an ISG that has decreased anti-* Corresponding author.
complementary activity, normal antigen binding, normal staphylococcal protein A binding and intact bactericidal activity (6, 9, 12, 23, 25) . However, reduction and alkylation decreases the Fc ability to bind to the first component of complement (6, 21, 35) . Complement activation does occur, however, primarily through the alternative pathway and with altered kinetics and decreased cooperativity (6, 21, 36) . In addition, Fc-mediated opsonization has been found to be abnormal (25, 32) . The decreased functional activity of reduced and alkylated ISG has thus far not been demonstrated to decrease protective activity against bacterial infection in vivo (9, 26 (2, 17) . Furthermore, this model provides multiple outcomes (bacteremia, meningitis, death) as well as quantitative outcome (magnitude of bacteremia), thus facilitating the evaluation of subtle but important differences in prophylactic regimens (17, 20, 29) .
MATERIALS AND METHODS
Intravenous immune serum globulins. Three preparations were used for comparison. All are fractionated from plasma by modifications of the cold ethanol procedure of Cohn et al. and Oncley et al. (8, 19) . Reduced and alkylated ISG (RA-ISG) was obtained commercially (Cutter Biologic Laboratories, Inc., Berkeley, Calif.) and is supplied as a 5% protein solution stabilized with 10% maltose. This ISG is prepared from Cohn fraction II that has been reduced with dithiothreitol and alkylated with iodoacetamide (12, 27 A standard serum containing 40 pRg of anticapsular antibody per ml was used for quantitation (22) .
Antibody to noncapsular Hib components was assayed by using an enzyme-linked immunosorbent assay to Hib noncapsular surface antigens. A Hib (strain Eagan) capsule-deficient mutant (supplied by Robert S. Daum, Tulane Medical Center, New Orleans, La.) was grown for 18 h in 200 ml of supplemented BHI broth. The bacteria were spun at 12,000
x g for 10 min at 4°C, and the pellet was washed twice in PBS and then resuspended in 1 M Tris buffer with 2.5 mM EDTA. Absorbance was determined on a spectrophotometer (Stasar II; Gilford Instruments, Oberlin, Ohio), and the bacteria were then sonicated on ice (Sonicator cell disrupter, Ultrasonics, Plainview, N.Y.) until a >50% decrease in absorbance was observed. The disrupted Hib cells were repelleted at 12,000 x g, the pellet was discarded, and the supernatant was saved and respun at 30,000 x g for 20 min
at 4°C. This new pellet was suspended in PBS, the protein concentration was assayed by the method of Lowry (16), and the solution was diluted to 1 ,ug/ml of protein concentration. Latex particle agglutination showed less than 1 ng of residual PRP per ml (33 Animal protection. Animals given saline and challenged with Hib sustained a high incidence of bacteremia and meningitis, a high cumulative death rate, and a high magnitude of blood bacterial density (Table 2) . Doses of pH4-ISG or RA-ISG containing large amounts of anti-PRP antibody protected infant rats from Hib infection; a globulin dose containing 3,000 ng of anti-PRP antibody given before Hib challenge prevented bacteremia, meningitis, and death when compared to saline injected controls ( Table 2) . One rat receiving RA-ISG at this dose developed low-grade transient bacteremia.
Lower doses of antibody revealed differences in protective efficacy between RA-, pH 4-, and UF-ISGs. Rats receiving RA-ISG containing 1,500 ng of anti-PRP antibody developed a higher incidence of bacteremia (40 versus 0%; P < 0.05) than rats receiving the same dose of pH 4-ISG. Similarly, at a dose of 750 ng of anti-PRP antibody, RA-ISG recipients, despite similar serum antibody levels, had significantly higher incidences of bacteremia, meningitis, and death as well as a higher magnitude of bacteremia than did pH 4-ISG recipients ( Table 2 ). The differences in protection afforded by the globulins persisted for the 5-day duration of the experiment (Fig. 1) . To ensure that the difference was not confined to single lots of RA-ISG and pH 4-ISG, two lots of each were examined and compared. Similar differences in protection were found (data not shown), and these data are therefore combined in Table 2 . Finally, a globulin prepared by a third method, ultrafiltration, showed similar efficacy as the pH 4-ISG.
To determine whether the protective activities of RA-and pH 4 nitude of bacteremia (P < 0.01) and a lower incidence of bacteremia, meningitis, and death than rats given absorbed RA-ISG (Table 3) . Serum anticapsular antibody levels. Serum anti-PRP antibody levels were measured in each rat pup to exclude the possibility that differences in protection were due to differences in the absorption and pharmacology of each ISG. Mean serum anti-PRP antibody levels were similar in each dosage group (Table 2) ng of anti-PRP antibody also maintained similar antibody levels over a 3-day period (Fig. 2) . The relationship between day 1 serum anti-PRP levels and bacteremia 24 h after Hib challenge is shown in Fig. 3 . Of rats receiving pH 4-ISG, 54% were protected from Hib infection when initial serum anti-PRP antibody levels were between 100 and 200 ng/ml. This contrasted with 6% protection in RA recipients with the same initial antibody levels (P < 0.01). The initial anti-PRP antibody level that protected 50% of pups receiving reduced and alkylated ISG from infection was approximately 100 ng/ml higher than native globulin recipients. DISCUSSION RA-ISG afforded less protection from bacteremia, meningitis, and death than native ISGs not reduced and alkylated in an infant rat model of Hib infection. The difference in efficacy was not due to differences in anti-PRP or noncapsular antibody content in the globulins, nor was it due to differences in anticapsular antibody levels in the infant rats which were similar in each dosage group. Decreased protective efficacy of RA-ISG was especially apparent at doses delivering borderline protective quantities of anti-PRP antibody.
The initial serum anti-PRP antibody level in rats predicted protection (Fig. 3) . The protective level of antibody in rats receiving native ISG was similar to that predicted for humans (22) . The serum concentration of anti-PRP antibody required for protection of infant rats challenged i.p. with Hib (100 to 200 ng/ml) was slightly higher than we reported previously in an intranasal rat model of Hib infection (2) . This difference is probably due to the larger number of organisms entering the circulation after i.p. injections than after intranasal administration (17, 18, 29) . The protective level of anti-PRP antibody in rats receiving RA-ISG was twofold higher, suggesting decreased function of the antibody in vivo.
The differences in protective effect of the ISGs were not due to differences in pharmacokinetics in the infant rats. UJninfected pups had similar anti-PRP antibody levels over a 3-day period after being given either RA-ISG or pH 4-ISG i.p. The differences in protective effect were also not due to different concentrations of antibody to noncapsular surface antigens of Hib. Enzyme-linked immunosorbent assay measurements of antibody titers confirmed that concentrations of somatic antibody were similar in RA-ISG and pH 4-ISG. Use of the PRP-absorbed ISGs in vivo showed some protective activity. Again, however, absorbed RA-ISG was significantly less protective than absorbed pH 4-ISG, suggesting decreased functional activity of antibody to noncapsular components of Hib in vivo.
The mechanism of the decreased efficacy of RA-ISG in protection of infant rats from Hib infection is unclear. Previous studies, as well as the current study, have documented normal in vitro cidal activity and antigen binding of RA-ISG. However, it seems clear that reduction and alkylation alters Fc function so that RA-ISG activates complement primarily through the alternative pathway. Function of the classical pathway, however, may be important to optimal host defense against bacterial infection. Bactericidal activity and opsonization by serum is more rapid when the classical pathway is intact (24) . An in vivo correlate of this finding exists in C4-deficient guinea pigs, which, when challenged with pneumococci, exhibit more rapid reappearance of bacteremia than normal animals and reduced protective activity of type specific antibody (14) . Although humans genetically deficient in early complement components are not always subject to infections, some C2-deficient humans have been found to be more susceptible to bacterial infections, including Hib, despite normal alternative pathway function (1, 35) .
The differences in efficacy of RA-ISG and less harshly treated ISGs were especially pronounced when low anticapsular antibody levels were present in infant rats. Others have shown that low levels of specific antibody to type III group B streptococcus utilizes the classical pathway, whereas pH 4-TREATED REDUCED AND ALKYLATED 
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higher antibody levels recruit the alternative pathway (10) .
Similar findings have recently been described for anti-PRP antibody (30) . Low levels of reduced and alkylated anticapsular antibody may thus be insufficient to activate adequate quantities of complement via the classical pathway for optimal promotion of bacterial lysis and opsonophagocytosis.
Previous studies have demonstrated that antibodies to noncapsular Hib components may also be protective in infant rats (13) . Our PRP-absorbed preparations containing anti-somatic antibodies were mildly protective at the concentrations given. PRP-absorbed RA-ISG, however, exhibited decreased protective efficacy compared to PRP-absorbed pH 4-ISG. The decreased protective efficacy of the PRP-absorbed RA-ISG may also be due to impaired complement activation by the noncapsular antibody in the preparation. Noncapsular antibody has recently been found to be unable to facilitate complement-mediated bactericidal activity via the alternative pathway (30) . Reduction and alkylation may further reduce complement, activation by these antibodies by decreasing C1Q binding necessary for classical pathway activation.
Other Fc-mediated functions of reduced and alkylated globulin, however, are also abnormal. Although opsonic activity of RA-ISG appears to be adequate in the presence of complement (25) , this ISG has decreased opsonic activity for a variety of organisms when no complement is present (32) . Since opsonization and subsequent clearance of Hib by the liver and spleen plays a major role in removal of Hib from the blood (34), alterations in Fc-receptor function might also result in decreased in vivo efficacy of RA-ISG. Whether due to poor classical pathway activation, altered opsonic ability, or other Fc-mediated function, intravenous RA-ISG exhibits decreased protective efficacy compared to two less harshly prepared ISGs in infant rats challenged with a common pediatric pathogen, Hib. Equivalent protection of infant rats required almost twofold more RA-ISG than native ISG as judged by rates of bacteremia, meningitis, and death as well as minimum protective antibody levels. If such a relationship holds true in human recipients, approximately twice as much RA-ISG than native ISG would be required to be administered to achieve protection from Hib infection. Further studies will be necessary to determine which functional defects of RA-ISG are responsible for decreased protective efficacy in vivo and whether protection against other bacterial pathogens is also impaired.
